Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002993 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Recurrent or Advanced Cancer of the Uterus
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00002993 is a Phase 2 study that was terminated before completion, run by Gynecologic Oncology Group. The registered enrollment target is 30 participants.
The verdict
NCT00002993, a Phase 2 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with mitomycin, doxorubicin, and cisplatin in treating patients with recurrent or advanced cancer of the uterus.
Interventions
- DRUG cisplatin
- DRUG doxorubicin hydrochloride
- DRUG mitomycin C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1997-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002993
The ClinicalTrials.gov registry entry for NCT00002993 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00002993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002993 about?
NCT00002993 is a clinical study titled "Combination Chemotherapy in Treating Patients With Recurrent or Advanced Cancer of the Uterus". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with mitomycin, doxorubicin, and cisplatin i...
What is the current status of trial NCT00002993?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 1997-08.
What interventions are being tested in trial NCT00002993?
The interventions under investigation include: cisplatin (DRUG), doxorubicin hydrochloride (DRUG), mitomycin C (DRUG).
Who is sponsoring clinical trial NCT00002993?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.